TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24824118
Drug: LDT +
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LDT + ADV combination therapy (LDT 600 mg plus ADV 10 mg orally, once daily)
Study: 24824118
Drug: LDT monotherapy
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LDT monotherapy
Study: 24824118
Drug: LDT +
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LDT + ADV combination therapy
Study: 22895856
Drug: Walnuts (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (75 g/day)
Study: 12198063
Drug: naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500 mg)
Study: 3266005
Drug: HbOC (Haemophilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC (Haemophilus influenzae type b mutant-diphtheria toxic conjugate vaccine)
Study: 3266005
Drug: HbOC (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC (after second dose at 4 months)
Study: 3266005
Drug: HbOC (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC (after third dose at 6 months)
Study: 30213449
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg oral per day) plus androgen deprivation therapy
Study: 28818054
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg/kg IV
Study: 26202168
Drug: Tomato sauce
Normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES TOMATO SAUCE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato sauce (142-198 g/d or 5-7 ounces/d)
Study: 26202168
Drug: Vegetable juice
Normalized name: Vegetable Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable juice (325-488 ml/d or 11-16.5 fluid ounces/d)
Study: 26202168
Drug: Lycopene-restricted control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-restricted control group (< 5 mg lycopene/d)
Study: 24286114
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 4.5 g/night (administered in 2 equally divided doses), with possible increases to 9 g/night or reductions to 4.5 g/night.
Study: 21384334
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of adjuvanted influenza A/09/H1N1 vaccine in patients with inflammatory rheumatic diseases
Study: 21384334
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of adjuvanted influenza A/09/H1N1 vaccine in healthy controls
Study: 21384334
Drug: Baseline antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline antibody levels in patients and controls
Study: 21384334
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose response in both groups
Study: 16616012
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (585 mg of docosahexaenoic acid and 225 mg of eicosapentaenoic acid)
Study: 8839521
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 10 to 15 micrograms/kg
Study: 8839521
Drug: Intramuscular meperidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine, promethazine, and chlorpromazine (MPC) 2 mg/kg meperidine, 0.5 mg/kg promethazine, 0.5 mg/kg chlorpromazine
Study: 1610630
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml kg‐1 of 4% glucose and 0.18% saline (group II)
Study: 23088514
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of yellow passion fruit peel flour for two months
Study: 21243915
Drug: 1xRDA MMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1xRDA MMS preparation (14 vitamins and minerals)
Study: 21243915
Drug: 2xRDA MMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2xRDA MMS preparation
Study: 21243915
Drug: Pooled effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled effect of MMS preparations
Study: 21243915
Drug: 1xRDA MMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1xRDA MMS preparation
Study: 17379121
Drug: 3xED(95) bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3xED(95) bolus dose of cisatracurium at induction
Study: 17379121
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cisatracurium during the entire procedure
Study: 15661841
Drug: Saline (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (sodium chloride 308 mmol/l)
Study: 12039705
Drug: Pulse of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse of insulin (0.03 U/kg s.c.) and dexamethasone (2 mg i.v.) with transient hyperglycemia
Study: 12039705
Drug: Insulin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.03 U/kg and 0.06 U/kg) with dexamethasone without transient hyperglycemia
Study: 12039705
Drug: Pulse of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse of insulin and glucose without dexamethasone
Study: 10534548
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (25 mg/ml prednisolone acetate)
Study: 1971118
Drug: 0.37 mg
Normalized name: menthol 0.37 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.37 mg alprazolam
Study: 394279
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (50 mg, rising to 150 mg per day)
Study: 26053030
Drug: Atazanavir (HIV-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (HIV-1 protease inhibitor)
Study: 22193796
Drug: Antipsychotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics with high risk of causing metabolic abnormalities
Study: 22193796
Drug: Antipsychotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics with medium risk of causing metabolic abnormalities
Study: 17351694
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (twice weekly)
Study: 9029748
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg for 1 day and 100 mg for 6 days)
Study: 9029748
Drug: Griseofulvin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (500 mg for 9 days)
Study: 7935655
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (400 mg/kg)
Study: 30423449
Drug: Peanut OIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut OIT with a maintenance dose of 125 to 250 mg peanut protein
Study: 23649189
Drug: ixabepilone 16
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ixabepilone 16 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm A: n = 46)
Study: 23649189
Drug: ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ixabepilone 40 mg/m(2) Q3W plus bevacizumab 15 mg/kg Q3W (Arm B: n = 45)
Study: 23649189
Drug: paclitaxel 90
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 90 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm C: n = 32)
Study: 21411446
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus simvastatin (GS) 250 mg/d and 40 mg/d respectively
Study: 21411446
Drug: Gefitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib alone (G) 250 mg/d
Study: 21411446
Drug: Gefitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib alone (G)
Study: 21411446
Drug: Gefitinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib alone (G) in patients with wild-type EGFR nonadenocarcinomas
Study: 14981107
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a), subcutaneous interleukin‐2 (sc‐IL‐2), and intravenous (IV) fluorouracil
Study: 14981107
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Arm A treatment combined with per oral 13‐cis‐retinoic acid
Study: 14981107
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a) and IV vinblastine
Study: 11577945
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day
Study: 11577945
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day plus Azithromycin 500 mg/day
Study: 9685820
Drug: iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol 320 mg I/ml
Study: 8995474
Drug: iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 300 mg I/ml
Study: 8015643
Drug: Levamisole (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2-3 mg/kg/day) twice a week for 12 months
Study: 2603453
Drug: Clindamycin 900
Normalized name: clindamycin 900 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 900 mg q8h admixed with gentamicin 1.5 mg/kg
Study: 2603453
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg q6h with gentamicin 1.5 mg/kg given separately
Study: 811982
Drug: Prindolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (2 x 5 mg daily)
Study: 811982
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prindolol (2 x 5 mg) + clopamide (10 mg)
Study: 28807045
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment plus renal artery stenting (stent group)
Study: 28807045
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT group)
Study: 22589424
Drug: Daily light
Normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 41 mg in 1 mL TOPICAL LOTION [DAILY LIGHT GUARD DEFENSE FLUID BROAD SPECTRUM SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily light smokers (3‐9 cigarettes/day)
Study: 21523384
Drug: Oily vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily vitamin D(3) preparation
Study: 21523384
Drug: Alcoholic vitamin
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic vitamin D(3) preparation
Study: 16922663
Drug: Lactose microencapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose microencapsulated vitamin D(3) 100 000 IU orally at baseline, then 3 monthly (three or more doses)
Study: 2792664
Drug: Loxiglumide (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (0.2, 1.0, or 5.0 mg/kg.h)
Study: 2792664
Drug: Loxiglumide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (1 or 5 mg/kg.h) with an 800-kcal meal
Study: 2792664
Drug: Loxiglumide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (5 mg/kg.h) without caerulein or the test meal
Study: 24944260
Drug: Droxidopa (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (100-600 mg 3 times daily)
Study: 15379738
Drug: Entacapone administered
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entacapone administered with 30 min delay
Study: 15379738
Drug: Co-administered entacapone
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered entacapone
Study: 15379738
Drug: Carbidopa/L-dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/L-dopa
Study: 11419239
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg.kg‐1 for induction, 0.12 mg.kg‐1.h‐1 for continuous infusion)
Study: 7954541
Drug: Low-dose combinations
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combinations of different diuretics (e.g., loop diuretics with thiazides)
Study: 2570959
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum with high antibody titre against human rotavirus
Study: 26011141
Drug: FPHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPHT sodium injection (400 mg PHT acid equivalent)
Study: 26011141
Drug: FPHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPHT sodium injection
Study: 26011141
Drug: PHT sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT sodium injection (400 mg PHT acid equivalent)
Study: 21812262
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of HSCT (Control)
Study: 20024753
Drug: Self-Administered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administered Therapy
Study: 17058023
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention for weight loss through exercise and diet modification, once weekly for 16 weeks.
Study: 1851063
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (3 pmol min‐1 kg‐1)
Study: 1851063
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no aldosterone infusion)
Study: 1851063
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (0.9% NaCl)
Study: 6794420
Drug: Metoprolol Durules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol Durules 200 mg o.m.
Study: 26401704
Drug: Phenserine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine treatment for 12 months
Study: 26401704
Drug: Phenserine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine treatment
Study: 21152932
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × CAF (6 mg kg(‐1) body mass caffeine, 1 h before exercise)
Study: 21152932
Drug: 3 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × CAF (2 mg kg(‐1) body mass caffeine on three separate occasions during the day)
Study: 21152932
Drug: PLA (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (0 mg caffeine)
Study: 19245438
Drug: PSD502 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSD502 (3 actuations of spray each containing 7.5 mg lidocaine and 2.5 mg prilocaine applied 5 min before intercourse)
Study: 15158628
Drug: Morphine (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (no open-label)
Study: 11150914
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (periCT) consisting of cyclophosphamide, epidoxorubicin, and 5-fluorouracil
Study: 11150914
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative chemotherapy (control)
Study: 29522648
Drug: Hyoscine hydrobromide
Normalized name: Hyoscine hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine hydrobromide 0.6 mg
Study: 9205824
Drug: Zamifenacin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zamifenacin 20 mg
Study: 8424420
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg intravenously
Study: 3319642
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide infusion
Study: 31464143
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone capsules
Study: 28591776
Drug: Nonaqueous mini‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonaqueous mini‐dose glucagon (MDG) (150 µg)
Study: 28591776
Drug: Glucose tablets
Normalized name: Glucose Tablets Orange Obsolete
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose tablets (TABS)
Study: 16965206
Drug: 4-step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-step treatment algorithm (washout period, anti-depressant monotherapy, lithium addition, treatment with a nonselective monoamine oxidase inhibitor, electroconvulsive therapy)
Study: 16965206
Drug: 4-step treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-step treatment algorithm
Study: 9798804
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 1 week (RbcCT)
Study: 9798804
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. for 2 weeks (RbcC)
Study: 360232
Drug: piracetam (Nootropil)
DrugBank: Piracetam (DB09210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: piracetam (Nootropil) 2400 mg/day
Study: 30630559
Drug: Dezocine-remifentanil intravenous
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine-remifentanil intravenous anaesthesia
Study: 30630559
Drug: Midazolam-remifentanil intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-remifentanil intravenous anaesthesia
Study: 10997483
Drug: estrogen/glucocorticoid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: estrogen/glucocorticoid combination
Study: 1580345
Drug: Short-term group
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term group treatment program for abusive husbands
Study: 3882059
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy feeds (3.6 MJ/L, 87 kcal/100 ml)
Study: 3882059
Drug: Standard energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard energy feeds (2.7 MJ/L, 65 kcal/100 ml)
Study: 26918239
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) plus timolol gel 0.05%
Study: 19370466
Drug: Diclofenac 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 3% gel followed by ALA-PDT
Study: 19370466
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel followed by ALA-PDT
Study: 16911579
Drug: Mitral isthmus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitral isthmus line (ML) recovery
Study: 15224297
Drug: 18 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 Gy radiation dose
Study: 15224297
Drug: 15 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 Gy radiation dose
Study: 3915461
Drug: Tenoxicam 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 1.2 mg/kg
Study: 9807845
Drug: Tenoxicam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 0.3 mg/kg
Study: 3915461
Drug: Tenoxicam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 0.6 mg/kg
Study: 31850931
Drug: GED‐0301 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED‐0301 (160 mg for 12 weeks followed by 40 mg continuously)
Study: 31850931
Drug: GED‐0301 (alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: GED‐0301 (alternating placebo with 40 or 160 mg every 4 weeks through week 52)
Study: 18814099
Drug: Prostanoids, nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostanoids, nonselective and selective endothelin-receptor antagonists, phosphodiesterase-V inhibitors
Study: 16870914
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (5 ppm) for 21 days or until extubation
Study: 10893362
Drug: Seratrodast, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seratrodast, 40 mg/d
Study: 3837566
Drug: Modified holding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified holding therapy (MHT)
Study: 24253831
Drug: FF 100
Normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 100 μg
Study: 9570244
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with metronidazole (500 mg twice daily for 2 weeks), amoxycillin (500 mg three times daily for 2 weeks), and omeprazole (20 mg once daily for 8 weeks)
Study: 9570244
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with amoxycillin (500 mg three times daily for 2 weeks) and omeprazole (20 mg once daily for 8 weeks)
Study: 28581818
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg a.m. and placebo p.m. (n=8)
Study: 28581818
Drug: metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 500 mg bid (n=8)
Study: 15198380
Drug: Cyanocobalamin, 1
Normalized name: Cyanocobalamin, 100 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin, 1 mg daily for 7 days, and 5 mg on the eighth day
Study: 15198380
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection daily for 8 days
Study: 2499825
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin (PHT)
Study: 28646924
Drug: Household-level prophylaxis
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household-level prophylaxis with single-dose ciprofloxacin
Study: 28646924
Drug: Village-wide prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Village-wide prophylaxis with single-dose ciprofloxacin
Study: 23351188
Drug: GM1 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 (100 mg once daily for 3 days)
Study: 23351188
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no neuroprotective agents)
Study: 20003436
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg per os daily
Study: 20003436
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1b every other day